BioCryst Pharmaceuticals has commenced a Phase I trial evaluating BCX4161 in healthy volunteers for the treatment of hereditary angioedema (HAE).

The study, being conducted at Quotient Clinical in the UK, is designed to assess the safety, pharmacokinetics and pharmacodynamics of BCX4161, a novel selective inhibitor of plasma kallikrein.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

BioCryst president and chief executive officer Jon Stonehouse said the daily, oral administration of a safe and effective prophylactic drug would revolutionise treatment for HAE patients.

"The study is designed to assess the safety, pharmacokinetics and pharmacodynamics of BCX4161, a novel selective inhibitor of plasma kallikrein."

"BCX4161 has the potential to be the first oral treatment developed specifically for the prevention of HAE attacks," Stonehouse said.

BioCryst BCX4161 previously demonstrated potent and selective inhibition of plasma kallikrein and an encouraging safety profile in nonclinical safety studies and in-vitro and in-vivo studies.

See Also:

The objectives of Phase I trial are to measure safety, characterise plasma drug levels and estimate the level of kallikrein inhibition achieved subsequent to oral dosing of BCX4161.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results of the study are anticipated in 2013.

If the objectives of the study are met, a Phase II programme in HAE patients is expected to be undertaken.